- Home
- FNF vs GMAB Comparison
FNF vs GMAB Comparison
Compare FNF & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNF
- GMAB
- Stock Information
- Founded
- FNF 1847
- GMAB 1999
- Country
- FNF United States
- GMAB Denmark
- Employees
- FNF N/A
- GMAB N/A
- Industry
- FNF Specialty Insurers
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FNF Finance
- GMAB Health Care
- Exchange
- FNF Nasdaq
- GMAB Nasdaq
- Market Cap
- FNF 16.0B
- GMAB 17.4B
- IPO Year
- FNF N/A
- GMAB N/A
- Fundamental
- Price
- FNF $56.58
- GMAB $29.99
- Analyst Decision
- FNF Strong Buy
- GMAB Strong Buy
- Analyst Count
- FNF 5
- GMAB 7
- Target Price
- FNF $71.00
- GMAB $41.17
- AVG Volume (30 Days)
- FNF 939.3K
- GMAB 2.9M
- Earning Date
- FNF 11-05-2025
- GMAB 11-06-2025
- Dividend Yield
- FNF 3.54%
- GMAB N/A
- EPS Growth
- FNF 16.93
- GMAB 77.72
- EPS
- FNF 3.93
- GMAB 21.62
- Revenue
- FNF $13,634,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- FNF $1.15
- GMAB $24.25
- Revenue Next Year
- FNF $10.81
- GMAB $16.29
- P/E Ratio
- FNF $14.36
- GMAB $1.38
- Revenue Growth
- FNF 7.26
- GMAB 32.97
- 52 Week Low
- FNF $50.61
- GMAB $17.24
- 52 Week High
- FNF $66.72
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- FNF 44.96
- GMAB 46.68
- Support Level
- FNF $54.60
- GMAB $29.57
- Resistance Level
- FNF $57.09
- GMAB $33.65
- Average True Range (ATR)
- FNF 1.15
- GMAB 0.73
- MACD
- FNF -0.03
- GMAB -0.52
- Stochastic Oscillator
- FNF 35.44
- GMAB 10.29
About FNF FNF Group of Fidelity National Financial Inc.
Fidelity National Financial Inc is a provider of (i) title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances and home warranty and (ii) transaction services to the real estate and mortgage industries. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. Substantially all of the company's revenue is generated in the United States.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.